New agents for AML and MDS.
The heterogeneity of acute myeloid leukaemia (AML) and myelodysplastic syndromes (MDS) has led to a multiplicity of treatments, from cytotoxic agents to signal transduction modulators, cell-cycle inhibitors and epigenetic therapies. While some have shown promising initial results, the outlook for AML patients, particularly older and relapsed patients, as well as patients whose cells exhibit certain adverse chromosomal abnormalities or mutant oncoproteins, continues to be grim. Combination chemotherapy using new agents that act at a number of different levels may provide the greatest potential for successful future therapies. A select number of new agents, approaches and combinations are reviewed here.
Grant
Steven
S
Department of Medicine, Virginia Commonwealth University and Massey Cancer Center, Richmond, VA 23298-0035, USA. stgrant@vcu.edu
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003603:Cytotoxins / Q000627:therapeutic use; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D009190:Myelodysplastic Syndromes / Q000188:drug therapy*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use
D003603:Cytotoxins; D047428:Protein Kinase Inhibitors